Abstract
One hundred eight patients were followed for a median of 99 months post alemtuzumab and were classified as active or nonactive after each cycle of treatment based on clinical relapse, increasing disability, or new T2/enhancing MRI lesions. This study does not support the use of cell counts as biomarkers for identifying patients at greater risk of active disease following treatment. See p. 2158 From editorialists Robertson & Scolding: “….the response to and continuing need for alemtuzumab, as with similarly acting or other disease-modifying treatments, remains unpredictable; the identification of validated and reproducible biomarkers in …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
